Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

TG2 protein is a key mediator in Porphyromonas gingivalis infection, study finds

Scientists at Forsyth, along with a colleague from Northwestern University, have discovered that the protein, Transgultaminase 2 (TG2), is a key component in the process of gum disease. TG2 is widely distributed inside and outside of human cells. The scientists found that blocking some associations of TG2 prevents the bacteria Porphyromonas gingivalis (PG) from adhering to cells. This insight may one day help lead to novel therapies to prevent gum disease caused by PG.

26 Mar 2014

Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

Case Western Reserve University researchers have discovered a novel population of neutrophils, which are the body's infection control workhorses. These cells have an enhanced microbial killing ability and are thereby better able to control infection.

25 Mar 2014

Certain drugs in Obamacare plans carry hefty pricetags

Insurers selling Obamacare plans have set drug prices according to a tiered system that in some cases requires consumers to pay as much as 50 percent of the cost, The Associated Press writes.

24 Mar 2014

First Edition: March 24, 2013

Today's early morning highlights from the major news organizations examine the final week for health law enrollment, the Supreme Court case this week about the law's contraceptive mandate and the fourth anniversary of the enactment of the controversial overhaul.

24 Mar 2014

Scientists discover key mechanism that guides balance and limb movements

Scientists at The Scripps Research Institute (TSRI) have discovered an important mechanism underlying sensory feedback that guides balance and limb movements.

17 Mar 2014

Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Same-day bilateral knee replacement surgery is safe for select patients with rheumatoid arthritis, researchers from Hospital for Special Surgery in New York have found.

14 Mar 2014

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Women are most likely to experience serious pain following knee replacement than men

Middle-aged women with rheumatoid arthritis or arthritis resulting from an injury are among the patients most likely to experience serious pain following a knee replacement, researchers from Hospital for Special Surgery (HSS) in New York have found.

12 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.

10 Mar 2014

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Aptel Research, a specialty marketing research and consulting company that provides actionable strategic insights to the pharmaceutical and biotech industries, released its newest report Patient Voices Series Rheumatoid Arthritis (US).

8 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Research to identify exact mechanisms behind preterm birth and fetal brain injury

An inflammatory protein that triggers a pregnant mouse's immune response to an infection or other disease appears to cause brain injury in her fetus, but not the premature birth that was long believed to be linked with such neurologic damage in both rodents and humans, new Johns Hopkins-led research suggests.

6 Mar 2014

Scientists discover fundamental aggravating factor in autoimmune diseases

Scientists in Freiburg may have discovered a fundamental aggravating factor in autoimmune diseases. If B-lymphocytes lack the protein PTP1B, the cells will become hyperactive for stimulatory signals and can thus promote an autoimmune attack.

6 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

The incidence of autism spectrum disorders has increased sharply since it was first described 60 years ago. Today, ASD affects more than 1% of all children in the U.S. and about half of them develop a life-long disability.

3 Mar 2014

New article explores risks associated with using herbal cannabis for rheumatic conditions

Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.

3 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

3 Mar 2014

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

TG2 protein is a key mediator in Porphyromonas gingivalis infection, study finds

Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

Certain drugs in Obamacare plans carry hefty pricetags

First Edition: March 24, 2013

Scientists discover key mechanism that guides balance and limb movements

Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Women are most likely to experience serious pain following knee replacement than men

Antares Pharma announces launch of OTREXUP to Dermatologists

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Research to identify exact mechanisms behind preterm birth and fetal brain injury

Scientists discover fundamental aggravating factor in autoimmune diseases

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

New article explores risks associated with using herbal cannabis for rheumatic conditions

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in